The emerging role of cystatins in Alzheimer's disease

BioEssays

Volumn 31, Issue 6, 2009, Pages 597-599

  Žerovnik, Eva ^a  

^a JO EF STEFAN INSTITUTE   (Slovenia)

Author keywords

Alzheimer's disease; Amyloid binding proteins; APP transgenic mice; Cathepsin B; Cystatin B; Cystatin C gene deletion; Neurodegeneration; Neuroprotection

Indexed keywords

AMYLOID BETA PROTEIN; CATHEPSIN B; CYSTATIN; CYSTATIN B; CYSTATIN C; STEFIN B;

ALZHEIMER DISEASE; ARTICLE; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; HUMAN; NEUROPROTECTION; NONHUMAN; PROTEIN AGGREGATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INTERACTION; RISK ASSESSMENT; RISK FACTOR; ANIMAL; GENETICS; METABOLISM; PATHOLOGY; TRANSGENIC ANIMAL;

ANIMALIA; MUS MUSCULUS;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; ANIMALS; ANIMALS, GENETICALLY MODIFIED; CATHEPSIN B; CYSTATINS; HUMANS;

EID: 67650138916     PISSN: 02659247     EISSN: None     Source Type: Journal    
DOI: 10.1002/bies.200900012     Document Type: Article

References (31)

1. Turk, V., Stoka, V. and Turk, D., Cystatins: biochemical and structural properties, and medical relevance. Front Biosci 2008. 13: 5406-5420.
2. Kopitar-Jerala, N., The role of cystatins in cells of the immune system. FEBS Lett 2006. 580: 6295-6301.
3. Turk, V., Turk, B. and Turk, D., Lysosomal cysteine proteases: facts and opportunities. EMBO J 2001. 20: 4629-4633.
4. Levy, E., Sastre, M., Kumar, A., Gallo, G., Piccardo, P., et al. Codeposition of cystatin C with amyloid-beta protein in the brain of Alzheimer disease patients. J Neuropathol Exp Neurol 2001. 60: 94-104.
5. Ii, K., Ito, H., Kominami, E. and Hirano, A., Abnormal distribution of cathepsin proteinases and endogenous inhibitors (cystatins) in the hippocampus of patients with Alzheimer's disease, parkinsonism-dementia complex on Guam, and senile dementia and in the aged. Virchows Arch A Pathol Anat 1993. 423: 185-194.
6. Hamano, T., Gendron, T. F., Causevic, E., Yen, S. H., Lin, W. L., et al. Autophagic-lysosomal perturbation enhances tau aggregation in transfectants with induced wild-type tau expression. Eur J Neurosci 2008. 27: 1119-1130.
7. Sastre, M., Calero, M., Pawlik, M., Mathews, P. M., Kumar, A., et al. Binding of cystatin C to Alzheimer's amyloid beta inhibits in vitro amyloid fibril formation. Neurobiol Aging 2004. 25: 1033-1043.
8. Kaeser, S. A., Herzig, M. C., Coomaraswamy, J., Kilger, E., Selenica, M. L., et al. Cystatin C modulates cerebral beta-amyloidosis. Nat Genet 2007. 39: 1437-1439.
9. Mi, W., Pawlik, M., Sastre, M., Jung, S. S., Radvinsky, D. S., et al. Cystatin C inhibits amyloid-beta deposition in Alzheimer's disease mouse models. Nat Genet 2007. 39: 1440-1442.
10. Levy, E., Cystatin C: a potential target for Alzheimer's treatment. Expert Rev Neurother 2008. 8: 687-689.
11. Finckh, U., von der Kammer, H., Velden, J., Michel, T., Andresen, B., et al. Genetic association of a cystatin C gene polymorphism with late-on-set Alzheimer disease. Arch Neurol 2000. 57: 1579-1583.
12. Cathcart, H. M., Huang, R., Lanham, I. S., Corder, E. H. and Poduslo, S. E., Cystatin C as a risk factor for Alzheimer disease. Neurology 2005. 64: 755-757.
13. Benussi, L., Ghidoni, R., Steinhoff, T., Alberici, A., Villa, A., et al. Alzheimer disease-associated cystatin C variant undergoes impaired secretion. Neurobiol Dis 2003. 13: 15-21.
14. Ghidoni, R., Benussi, L., Paterlini, A., Missale, C., Usardi, A., et al. Presenilin 2 mutations alter cystatin C trafficking in mouse primary neurons. Neurobiol Aging 2007. 28: 371-376.
15. Benussi, L., Binetti, G. and Ghidoni, R., Cystatin C role in Alzheimer's disease: from neurodegeneration to neuroregeneration. In: Zerovnik, E., Kopitar-Jerala, N. and Uversky, V. N. editors. "Human stefins and cystatins", Molecular anatomy and physiology of proteins series. New York, Nova Science Publishers, 2006. pp 115-125.
16. Ishimaru, H., Ishikawa, K., Ohe, Y., Takahashi, A. and Maruyama, Y., Cystatin C and apolipoprotein E immunoreactivities in CA1 neurons in ischemic gerbil hippocampus. Brain Res 1996. 709: 155-162.
17. Katakai, K., Shinoda, M., Kabeya, K., Watanabe, M., Ohe, Y., et al. Changes in distribution of cystatin C, apolipoprotein E and ferritin in rat hypothalamus after hypophysectomy. J Neuroendocrinol 1997. 9: 247-253.
18. Lukasiuk, K., Pirttila, T. J. and Pitkanen, A., Upregulation of cystatin C expression in the rat hippocampus during epileptogenesis in the amygdala stimulation model of temporal lobe epilepsy. Epilepsia 2002. 43: 137-145.
19. Palm, D. E., Knuckey, N. W., Primiano, M. J., Spangenberger, A.G. and Johanson, C. E., Cystatin C, a protease inhibitor, in degenerating rat hippocampal neurons following transient forebrain ischemia. Brain Res 1995. 691: 1-8.
20. Olsson, T., Nygren, J., Hakansson, K., Lundblad, C., Grubb, A., et al. Gene deletion of cystatin C aggravates brain damage following focal ischemia but mitigates the neuronal injury after global ischemia in the mouse. Neuroscience 2004. 128: 65-71.
21. Pirttila, T. J., Lukasiuk, K., Hakansson, K., Grubb, A., Abrahamson, M. and Pitkanen, A., Cystatin C modulates neurodegeneration and neurogenesis following status epilepticus in mouse. Neurobiol Dis 2005. 20: 241-253.
22. D'Amato, E., Kokaia, Z., Nanobashvili, A., Reeben, M., Lehesjoki, A. E., et al. Seizures induce widespread upregulation of cystatin B, the gene mutated in progressive myoclonus epilepsy, in rat forebrain neurons. Eur J Neurosci 2000. 12: 1687-1695.
23. Mueller-Steiner, S., Zhou, Y., Arai, H., Roberson, E. D., Sun, B., et al. Antiamyloidogenic and neuroprotective functions of cathepsin B: implications for Alzheimer's disease. Neuron 2006. 51: 703-714.
24. Hook, V., Kindy, M. and Hook, G., Cysteine protease inhibitors effectively reduce in vivo levels of brain beta-amyloid related to Alzheimer's disease. Biol Chem 2007. 388: 247-252.
25. Hook, V. Y., Kindy, M. and Hook, G., Inhibitors of cathepsin B improve memory and reduce beta-amyloid in transgenic Alzheimer disease mice expressing the wild-type, but not the Swedish mutant, beta-secretase site of the amyloid precursor protein. J Biol Chem 2008. 283: 7745-7753.
26. Sun, B., Zhou, Y., Halabisky, B., Lo, I., Cho, S. H., et al. Cystatin C-cathepsin B axis regulates amyloid beta levels and associated neuronal deficits in an animal model of Alzheimer's disease. Neuron 2008. 60: 247-257.
27. Nagai, A., Ryu, J. K., Terashima, M., Tanigawa, Y., Wakabayashi, K., et al. Neuronal cell death induced by cystatin C in vivo and in cultured human CNS neurons is inhibited with cathepsin B. Brain Res 2005. 1066: 120-128.
28. Yang, D. S., Stavrides, P., Mohan, P., Kumar, A., Schmidt, S. D., et al. Cystatin B deletion in a mouse model of Alzheimer's disease, TgCRND8, ameliorates both autophagiclysosomal and amyloid pathologies. Alzheimer's & Dementia 2008. 4: T223-T223. P1-059.
29. Di Giamo, R., Riccio, M., Santi, S., Galeotti, C., Ambrosetti, D. C. and Melli, M., New insights into the molecular basis of progressive myoclonus epilepsy: a multiprotein complex with cystatin B. Hum Mol Genet 2002. 11: 2941-2950.
30. Cipollini, E., Riccio, M., Di Giaimo, R., Dal Piaz, F., Pulice, G., et al. Cystatin B and its EPM1 mutants are polymeric and aggregate prone in vivo. Biochim Biophys Acta 2008. 1783: 312-322.
31. Čeru, S., Mechanism of cytotoxicity of prefibrillar aggregates of stefin B and some chosen mutants in vitro and ex vivo. PhD Thesis, Medical Faculty, University of Ljubljana 2008.